2Toshiyuki Yano.Neuroprotective Effect of Urinary Trypsin Inhibitor against Focal Cerebral Ischemia-Repeffusion Injury in Rats.Anesthesiology,2003,98:465-473.
3Angus DC,Linde-Zwirble WT,Lidicker J,et al.Epidemiology of severe sepsis in the United States:analysis of incidence,outcome and associated costs of care.Crit Care Med,2001,29:1303-1310.
4Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis:ACCP/SCCM Consensus Conference Committee.Chest,1992,101:1644-1655.
5Marshall JC,Cook DJ,Christou NV,et al.Multiple organ dysfunction score:A reliable descriptor of a complex clinical outcome.Crit Care Med,1995,23:1638-1652.
6Dellinger RP,Carlet JM,Masur H,et al.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.Crit Care Med,2004,32:858 -873.
7Cronin L,Cook DJ,Carlet J,et al.Corticosteroid treatment for sepsis:a critical appraisal and meta-analysis of the literature.Crit Care Med,1995,23:1430-1439.
8Natanson C,Esposito C J,Banks SM.The sirens' songs of confirmatory sepsis trials:selection bias and sampling error.Crit Care Med,1998,26:1927-1931.
9Bone RC.Sir Isaac Newton,sepsis,SIRS,and CARS.Crit Care Med,1996,24:1125-1128.
10Richard S Hotchkiss,Irene E Karl.The pathophysiology and Treatment of Sepsis.N Engl J Med,2003,348:138-150.
3Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012 [ J ]. JAMA, 2014,311 ( 13 ) : 1308- 1316.
4Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the intensive care over na- tions ( ICON ) audit [ J ]. Lancet Respir Med, 2014,2 ( 5 ) : 380- 386.
5Cohen J, Vincent JL, Adbikari NK, et al. Sepsis: a roadmap for fu- ture research [ J ]. Laneet Infect Dis, 2015,15 ( 5 ) : 581-614.
6Inee C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis [J ]. Shoek, 2016, 45 ( 3 ) : 259-270.
